ArticleParasites & vectors2026
Why are iron chelators not as effective as artemisinin in killing malaria parasites?
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundArtemisinin resistance endangers current artemisinin combination therapy (ACT), necessitating new ACT development. Artemisinin kills malaria parasites by generating free radicals via heme/iron activation, while iron chelators disrupt iron utilization. The combination of these two mechanisms may form a better antimalarial therapy. It is known that iron chelators have significantly weaker antimalarial effects than artemisinin, but the mechanism is unclear. Thus, clarifying this reason is essential for elucidating artemisinin's antimalarial action and developing strategies to enhance ACT.
methodsWe assessed the effects of artemisinin derivatives (dihydroartemisinin, DHA; artemether, ATM) and the iron chelator desferrioxamine (DFO) on parasite infection rate and morphology in vitro/in vivo. Single-cell RNA sequencing was used to compare Plasmodium falciparum 3D7's sensitivity to DHA/DFO at 3, 9, and 24 h post-treatment, analyzing differential gene expression and affected functions. Transmission electron microscopy (TEM) was used to observe artemisinin's impact on parasites.
resultsAlthough all developmental stages of P. falciparum 3D7 exhibited sensitivity to 24-h DHA treatment, parasite counts at 12-30 h postinfection (hpi) decreased more rapidly following 9-h DFO treatment than 9-h DHA treatment. Notably, DHA upregulated iron utilization-related genes at 3 h post-treatment (hpt), whereas DFO did not. DHA and DFO exerted distinct effects on gene expression, particularly in parasites at 12-30 hpi, where DHA induced the expression of genes related to ribosome biogenesis and protein translation pathways. In functional assays, DFO reduced P. falciparum parasitic infection in vitro but failed to inhibit P. yoelii proliferation in vivo; the combination of ATM and DFO was less potent than ATM monotherapy. TEM observations revealed that ATM localized to the parasites' digestive vacuoles and disrupted heme aggregation.
conclusionsArtemisinin and its derivatives exhibit more potent antimalarial activity than iron chelators, likely stemming from their ability to accumulate in the parasite's digestive vacuoles, interact more effectively with heme and iron, and thereby disrupt heme/iron homeostasis and utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.